Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) The trials were ...

The risk-based screening strategy was associated with similar detection rates for any cancer compared with annual screening (423.6 vs 410.9 per 100,000 person-years), stage IIA or higher tumors (88.7 ...